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1. Introduction 
Vasculitis is defined as chronic blood vessel inflammation confirmed by histologic evidence. 
The typical course of the disease may lead to blood vessel stenosis/occlusion causing organ 
ischemia, or to thinning of the blood vessel which results in aneurysm formation or 
hemorrhage. Although in 1994 the American College of Rheumatology introduced 
morphological and histopathological classification criteria for the most common forms of 
vasculitides at the Chapel Hill Consensus Conference (CHCC) (Jennette et al., 1994), 
vasculitides are generally divided into two main categories. Primary vasculitides represent 
the first group, are the entities of unknown cause in which blood vessel inflammation is the 
pathologic basis of tissue injury. Secondary vasculitides constitute the second, 
heterogeneous and much bigger group, in which inflammatory process occurs in association 
with an underlying disease or exposure.  
The pathophysiology of the vasculitides is based on immunologic mechanisms. These 
mechanisms appear to play an active role in mediating the inflammatory response, but 
precise mechanisms still remain poorly understood. Although the primary events that 
initiate this process remain largely unknown, recent investigations have brought us closer to 
understanding some of the critical pathways involved in disease and provided a rationale 
for the study of novel therapeutic agents (Langford, 2010).  
Intravenous immunoglobulin (IVIG) represents one of the novel alternative choices for the 
treatment as the standard regimen and IVIG has now become an important option in a 
number of clinical indications beyond primary immunodeficiency, including vasculitides.  
2. Mechanisms of action   
When Burton in 1951 for the first time published experience with the use of 
immunoglobulins in the replacement therapy for patients with primary immunodeficiencies 
and later other authors for secondary immunodeficiencies, no one would have expected that 
it could lead to the contemporary wide use of IVIG. Immunoglobulins can be applied in 
several immunomodulatory and anti-inflammatory indications as well. However, the exact 
mechanisms of action are only tentative. Some pathogenetic aspects have been already 
described, but during last fifteen years of intensive research new perspectives in 
understanding immunologic mechanisms of IVIG effects were introduced. 
Basic immunomodulatory mechanisms of IVIG in autoimmune and inflammatory diseases 
could be devided into two groups. The first group involves mechanisms of humoral 
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immunity and the second one involves mechanisms of cell-mediated immunity. Both groups 
interdependently involve modulation of expression and function of Fc receptors, 
interference with complement activation and the cytokine network, provision of 
antiidiotypic antibodies, modulation of dendritic cells, T and B-cell activation and 
differentiation and their effector functions (Negi et al., 2007). 
Intravenous immunoglobulins are prepared from pooled normal polyspecific human IgG 
obtained from large numbers of healthy donors. IVIG thus contains the wide spectrum of 
natural antibodies that far exceeds spectrum present in individual subjects. Essential roles of 
natural antibodies in healthy subject are: first line defense against infection, clearance of 
aging cells, antigen presentation to T-cells, anti-tumoral surveillance, anti-inflammatory 
activity and selection of immune repertoires and homeostasis of autoreactivity (Lacroix-
Desmazes et al., 1998).  
2.1 Natural antibodies in IVIG 
Immunomodulatory effect of IVIG is probably dependent on the content of natural 
antibodies in treatment preparations because it is hypothesized that the presence of natural 
antibodies in healthy subjects control autoreactivity and maintain immune homeostasis. 
IVIG preparations contain sampling from the entire array of variable regions of antibodies, 
so they play an important role in selection of autoreactive B-cells and prevent uncontrolled 
expansion of specific autoreactive clones in disease. In addition, natural antibodies may play 
a role in prevention of the occurrence of pathological autoimmune reactions by binding to 
microbial epitopes that are similar or identical to self antigens (Cohen & Cooke, 1986). 
Superantigens trigger the activation of autoreactive cells. IVIG contain anti-antibodies which 
could eliminate superantigens such as toxic shock syndrome toxin 1 and Staphylococcal 
enterotoxins. These superantigens are generally considered to be the triggers of exacerbation 
in Wegener´s granulomatosis (WG) (Stegeman et al., 1994, Boros et al., 2005).   
2.2 Effect on Fc receptor modulation and anti-inflammatory activity 
In order to prevent intracellular degradation of immunoglobulins in normal conditions Fc-
receptor (FcRn) binds the molecule IgG inside the lysosome. During IVIG treatment 
oversaturation of normal molecules result in the accelerated catabolism of IgG and therefore 
reduce the level of pathogenic autoantibodies. In addition such IgG saturation leads to 
downregulation of FcRn in lysosomes and amplifies the effect of such treatment (Yu & 
Lennon, 1999). This hypothesis was supported in an experimental model, where in FcRn 
knockout mice, IVIG did not increase the clearance of antibodies, while in the wild type 
animals it did (Hansen & Balthasar, 2002). Analogous to normal circulating 
immunoglobulins intravenous immunoglobulins have also anti-inflammatory properties 
which modulate systemic inflammation during various inflammatory pathologies. Kaneko 
et al., (2006) showed that distinct properties of the Fc segment of IgG result from differential 
sialylation of the Fc core polysaccharide. IgG acquires anti-inflammatory properties upon Fc 
sialylation, which is reduced upon the induction of an antigen-specific immune response.        
2.3 Immunomodulatory role of antiidiotypic antibodies 
IVIG contains anti-idiotypes which are capable to neutralize pathogenic autoantibodies as 
described in antiphospholipid syndrome (Sherer et al., 2000) and idiopathic 
trombocytopenic purpura (Hoffmann et al., 2000). Interaction between antiidiotypes (Fab 
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binding site) from IVIG and idiotype receptors on B-cells is probably responsible for the 
regulatory effect on autoreactive B-cell clones in patients with autoimmune and 
inflammatory disorders. Leucht et al., (2001) showed selective (VH gene origin) B-cell 
activation after IVIG treatment on patient with Kawasaki disease (KD). Sequence analysis 
has revealed that the most frequently used germ-line gene segments of all IVIG-bound Fabs 
were identical to those observed for many other autoantibodies and also represent the most 
frequently rearranged VH genes among human B-cells. It suggests that anti-idiotypic 
interactions may have an important role for the development and the control of the B-cell 
repertoire (Sibéril et al., 2007).         
2.4 Dendritic cells as a target of immunomodulatory effect 
Defective functions of dendritic cells have also been attributed for predisposition in 
vasculitis pathology. Bayary et al. (2006) have shown that dendritic cells are influenced by 
IVIG at therapeutic concentrations (25 – 35 mg/ml) in terms of modulation of 
differentiation, maturation and function of dendritic cells. They observed that IVIG 
abrogates secretion of IL-12, downregulates the capacity of mature and immature dendritic 
cells to express costimulatory molecules (CD80, CD86, CD40) which results in inhibition of 
auto- and alloreactive T-cell activation and proliferation. Providing that the suppression of 
these signals is necessary for optimal antigen presentation and T-cell activation, it could be 
plausible explanation of the efficacy of IVIG in many immuno-inflammatory diseases 
including vasculitides.   
2.5 Regulation of cytokine production 
IVIG shows anti-inflammatory effect in vasculitis by modulation of cytokine antagonists 
and Th1 and Th2 cytokine production. Andersson et al. (1996) published that the addition of 
IVIG (6 mg/ml) to stimulated cell cultures of peripheral blood mononuclear cells caused a 
marked inhibition of proliferation and blast transformation despite unaffected cell survival. 
These cells exhibited a significant inhibition of production of T-cell derived cytokines IL-2, 
IL-10, TNF-beta, IFN-gamma. Gupta et al. (2001) found reduction of proinflammatory 
cytokines Il-6, Il-8 and TNF-alfa in patients with KD. Lau et al. (2009) confirmed in murine 
model of KD that IVIG in therapeutic concentrations, but not salicylate, effectively reduced 
the immune response leading to TNF-alpha expression. Possible mechanism published 
Siedlar et al. (2011) when in vitro exposure of the healthy individuals' monocytes to the IVIG 
preparation resulted in reduced TNF production, which was overcome by blockade of the 
FcγRIIB in the CD14(+) CD16(++) CD32B(high) monocytes. Reduction in the number of 
CD14(+) CD16(++) monocytes and the blockade of their cytokine production via triggering 
CD32B can contribute to the anti-inflammatory action of IVIG. Regulation of cytokine and 
cytokine antagonists production is supposed to be one of the major anti-inflammatory 
mechanisms of intravenous immunoglobulins.  
2.6 Attenuation of complement activation 
Pathomechanisms of some vasculitides are closely associated with complement activation. 
Cryoglobulinemic vasculitis (glomerulonephritis) in patients with hepatitis C is associated 
with hypocomplementemia caused by its consumption (D´Amico & Fornasieri, 1995). In 
these patients various complement components such C3 and C1q has been detected in the 
different tissues (Haydey et al., 1980). IgA deposition, as well as complement factors (C3, 
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properdin, and complement membrane attack), were detected in mesangion in patients with 
Henoch-Schönlein purpura (HSP) complicated by nephritis (Bene & Faure, 1987). Deposition 
of C3, C4, MBL but no  C1q were detected in an other study (Hisano et al., 2005). Association 
of complement activation in vasculitides is not clearly understood. The mentioned studies 
showed that the complement system could be activated both through the alternative and 
classical/lectin pathway in patients with HSP. In ANCA-associated vasculitides interaction 
among ANCA, neutrophils and complement suggests a role of these components in the 
development of the disease. The ANCA-activated neutrophils release factors that can 
directly damage the endothelium but also activate the alternative complement pathway 
with the generation of the powerful neutrophil chemoattractant C5a. C5a and neutrophil 
C5aR may thus compose an amplification loop for ANCA-mediated neutrophil activation. 
Complement activation amplifies neutrophil influx and activation eventually culminates in 
severe necrotizing inflammation of the vessel wall in ANCA-associated vasculitides (Chen 
et al., 2010).   
2.7 Regulation of T and B-cells 
In normal condition T-cells and B-cells are important for the control of autoreactivity and 
induction of tolerance. In vasculitides, as well as in other autoimmune diseases, T-cells most 
likely play a role in delivering proper signals to autoreactive B-cells for the production of 
autoantibodies (Negi et al., 2007). T-cells probably also participate in granuloma formation 
in Wegener´s granulomatosis (Heeringa et al., 2005). In granulomatous lesions of WG T-cells 
with fenotype CD4+, CD28- represents a major source of proinflammatory cytokines (TNF-
alfa, IFN-gamma) and may function as an essential driving force for perpetuating 
inflammation (Holle & Gross, 2009). These interactions indicate that an aberrant signaling 
cascade could be activated. Membrane molecules of T and B-cells could react with IVIG. In 
the last two decades many authors described that IVIG contain antibodies against variable 
membrane molecules variable such as CD4, CD5, CD40, CD95 and cytokine receptors and a 
variable amount of solubilised CD4, CD8, HLA-I and HLA-II molecules (Ephrem et al., 
2005). Pool of antibodies stored in intravenous immunoglobulins directed to such functional 
molecules of lymphocytes is important for the immunomodulatory effects of IVIG and may 
interfere with antigen recognition by the T-cells (Blasczyk et al., 1993). 
2.8 Modulation of Th17 cell function 
Recently discovered regulatory Th17-cells and cell-derived cytokines play an important role 
in the pathogenesis of several autoimmune/inflammatory diseases including vasculitides. 
In Wegener´s granulomatosis, regulatory T-cells display impaired suppressor activity 
potentially favouring inflammation and break of tolerance (Abdulahad et al., 2007). Th17 -
cells produce several cytokines such as Il-17, Il-21, IL-22, CCL-20 which induce massive 
inflammatory tissue reactions and these cytokines also stimulate nonimmune cells 
(fibroblasts, endothelial and epithelial cells) to the production of other proinflammatory 
mediators (Il-6, TNF-alfa, prostaglandins, NO, MMP and chemokines (Miossec et al., 2009). 
Maddur et al. (2011) published their results concerning the inhibition of differentiation, 
amplification and function of Th17-cells by IVIG treatment. The inhibitory effect depends on 
Fab2 receptor on Th17-cells. Maddur concluded that inhibition of effector cytokine release 
(Il-17A, IL-17F, IL-21) by these cells could demonstrate efficacy of IVIG in patient with 
autoimmune diseases by newly discovered mechanism.    
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3. Clinical indications  
Intravenous immunoglobulins contain many different types of immune globulins 
(differentiated on the basis of structure and biological activity) that target different specific 
immune functions of the body. In this way, immunoglubulins imparts several types of 
immune fighting antibodies simultaneously. Seeing that the precise mechanism of IVIG are 
still largely unknown, the therapeutic mechanism of low-dose and high-dose regimen, as 
well as the short-and long-term effects are not the same for each condition. In low-dose and 
long term regimen IVIG were initially used to treat immunodeficiencies. Controversial 
knowledge about effectivity of high-dose treatment regimens leads to organizing several 
scientific meetings where attempt for treatment guidelines has been emphasized. In 2007 
EULAR recommendations for the management of primary vasculitides were published in 
two parts according to CHCC classification - recommendations for small & medium vessel 
vasculitides and recommendations for large vessel vasculitides. These recommendations 
have been developed according to standardized operating procedures by EULAR standing 
committees. The guidance needs to be tailored to meet individual requirements. It is 
intended for use by healthcare professionals, medical students and specialist trainees, and 
pharmaceutical industries and drug regulatory organizations (Mukhtyar et al., 2009a, b). 
The British Society for Rheumatology published by Lapraik et al. (2007) guidelines for the 
management of adult ANCA-associated vasculitides. The main need for guidelines was to 
review the current treatment protocols and to highlight where there is an evidence base for 
treatment protocols and where treatment is based on individual preference. 
Recommendations are classified according to the level of evidence and the strength of 
recommendation. For large vessel vasculitides there is no place for IVIG according to EBM 
recommended treatment choice. For small and medium vessel vasculitides in statement 11 – 
“Alternative immunomodulatory therapy” – for patients who fail to achieve remission and 
have persistent low activity intravenous immunoglobulin can be used to achieve remission. 
These patients should be referred to an expert centre for further management and enrolment 
in clinical trials (level of evidence 3, grade of recommendation C). Contraindications of such 
treatment protocol are patients with selective IgA deficiency who may develop an 
anaphylactic reaction and patients with hypergamaglobulinaemia with risk of 
hyperviscosity state. Accorging to BSR guidelines (Lapraik et al., 2007) IVIG may be 
considered as an alternative therapy in patients with refractory disease or in patients for 
whom conventional therapy is contraindicated, for example, in the presence of infection, in 
the severely ill patient or in pregnancy (grade of recommendation B). In the management of 
refractory vasculitis it is important to identify drives for vasculitis, such as, intercurrent 
infection or malignancy, or non-compliance.           
3.1 Kawasaki disease 
Clinical criteria and the exclusion of other conditions, including sepsis define the diagnosis 
of Kawasaki disease (Brogan et al. 2002). After the estimation of correct diagnosis the 
treatment regimes are focused on reducing inflammation and preventing vascular 
complications. Coronary artery abnormalities develop within 8 weeks of Kawasaki disease 
onset. Males and young children are most at risk. No IVIG treatment is considered to be one 
of the positive risk factor for Kawasaki disease cardiac complications (Phillip & Luqmani, 
2008). So that, besides the standard regimes IVIG represent approved choice of treatment in 
KD with one basic aim – directly reduce the risk of developing coronary artery 
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abnormalities. The highest doses of IVIG were associated with the lowest risk late coronary 
complications. Meta-analysis study (Durongpisitkul et al., 1995) of treatment studies 
showed that a single high-dose of IVIG (>1g/kg) in combination with aspirin reduced 
coronary artery abnormality formation from 23% to 2.3%. Japan research committee 
reported one trial using low-dose of IVIG (100 mg/kg as a single dose) which showed no 
significant difference between the treatment groups in term of the occurrence of coronary 
artery abnormalities. It should emphasized that high-dose IVIG treatment in acute phase of 
KD have to start as soon as possible after diagnosis (Newburger et al., 1986).   
3.2 Polyarteritis nodosa 
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium or small 
arteries characterized by a wide variety of clinical features including fever, constitutional 
symptoms, and systemic involvement (muscles, joints, intestines, nerves, kidneys, and skin). 
Asano et al. (2006) postulated that the effect of IVIG therapy on PAN is temporary, but in 
situation that PAN is induced by infections, IVIG therapy leads to a complete remission of 
the disease due to the neutralization of immune activation triggers, such as Parvovirus B19 
and Streptococcus. Also Girisgen et al. (2011) based on the case report of 7 years old girl 
with polyarteritis nodosa and Henoch–Schönlein purpura nephritis suggested that IVIG 
might be an important adjunct therapy in selected patients with polyarteritis nodosa, 
especially in the lack of response to steroids and immunosuppressive drugs. On the contrary 
González-Fernández & García-Consuegra (2007) published the case-report of a child with 
polyarteritis nodosa that was unresponsive to conventional treatment, as well as IVIG 
treatment during her first and second hospitalizations. Treated child was successfully 
improved after the addition of iloprost and bosentan.   
3.3 Wegener´s granulomatosis and microscopic polyangiitis 
Wegener’s granulomatosis is a rare disorder which is characterized by necrotizing 
granulomatous vasculitis of small vessels. WG mainly affects the upper and lower 
respiratory tract, the kidneys, joints, skin and eyes in contrary to microscopic polyangiitis 
(MPA) which is characterized by pauci-immune, necrotizing, small-vessel vasculitis without 
clinical or pathological evidence of necrotizing granulomatous inflammation. MPA usually 
affects the kidneys, nervous system (particularly the peripheral nerves), skin, and lungs.  
Some authors mention that WG, MPA even the Churg-Strauss syndrome (CSS) form a part 
of a spectrum of one disease rather than entirely different entity (Kallenberg, 2005) and 
PAN. In a view of such classification more accurately criteria are expected. Watts et al. in 
2007 published reclassification of ANCA-associated vasculitides and PAN which would be 
applied into clinical research in the future. This classification allows less unclassified 
patients and overlapping diagnosis in epidemiological studies as well as in pharmacological 
trials of various treatment regimes. Until present no study was realized by using this criteria 
and the evaluation of IVIG treatment in ANCA-associated vasculitides allows us to join WG 
and MPA under one condition. Moreover the role of IVIG for the treatment of ANCA 
associated vasculitides has not been clearly defined. IVIG treatment of these entities is 
frequently discussed subject of many scientific contributions. Jayne et al. (2000) published 
the only randomized placebo controlled trial of 34 patients with WG/MPA and found that a 
single course of IVIG reduced disease activity in persistent ANCA associated vasculitides, 
but this effect was not maintained beyond three month. Side effects were frequent, but mild 
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and reversible. Authors advise IVIG as an alternative treatment in persistent disease after 
standard therapy. Martinez et al. (2008) published results of multicenter, prospective, open-
label study of 22 patients (19 with WG and 3 with MPA) and concluded that IVIG induced 
complete remissions of relapsed ANCA-associated vasculitides in 13 of 22 patients at nine 
months. Because of the good safety and tolerance profiles of IVIG, these agents can be 
included in a therapeutic strategy with other drugs used to treat relapses of WG or MPA. In 
2009 Fortin et al. reanalyzed data from 187 publications and found the only randomized 
controlled trial published by Jayne et al. in 2000. The main aim of Frontin´s review was to 
determine if intravenous immunoglobulin adjuvant therapy provides a therapeutic 
advantage over treatment with systemic corticosteroids in combination with 
immunosuppressants for the treatment of WG. After data extraction and statistical analysis 
Frontin concluded that there were no significant differences between adjuvant IVIG and 
adjuvant placebo in mortality, serious adverse events, time to relapse, open-label rescue 
therapy and infection rates. The fall in disease activity score, derived from patient-reported 
symptoms, was slightly greater in the IVIG group than in the placebo group after one 
month. Total adverse events in the IVIG group were increased 3,5 times (relative risk (RR) 
3.50; 95% CI 1.44 to 8.48, P < 0.01). General conclusion from published Cochrane review is 
that there is insufficient evidence for comparing the advantages of IVIG adjuvant therapy to 
the treatment using the combination of steroids and immunosuppressants for patients with 
WG. Hiemstra & Jayne (2009) recommended in situations where glucocorticoids and 
immunosuppressives are contraindicated or represent an unacceptably high infection risk 
that IVIG may be considered; these include the presence of sepsis, a patient in intensive care 
unit or in pregnancy. IVIG cannot be recommended for routine use in ANCA-associated 
vasculitides, but can be considered where conventional agents are ineffective or 
contraindicated. Chung & Seo (2009) in general evaluation of advances in use of biological 
agents for the treatment of systemic vasculitides summarized that IVIG is not a panacea but 
play a role as adjunctive therapy for disease refractory to routine immunosuppression. IVIG 
may also be useful for patients in whom immunosuppression is undesirable or 
contraindicated (pregnancy). 
3.4 Churg-Strauss syndrome  
Churg-Strauss syndrome (CSS) is characterized by the presence of asthma, eosinophilia, and 
small vessel vasculitis with granuloma. Hamilos & Christensen first reported in 1991 that a 
33-year-old man with CSS, who was resistant to conventional steroid treatment, showed a 
marked improvement of vasculitis symptoms and normalization of eosinophil count after 
IVIG therapy. However, there have been only a few reports on the use of IVIG therapy for 
CSS (Taniguchi et al., 2007). In 2004 Tsurikisawa et al. reported that neurological and cardiac 
manifestations in 15 patients with CSS, who were not responsive to corticosteroids with or 
without cyclophosphamide, were significantly improved after IVIG therapy. Intravenous 
immunoglobulin therapy may also be considered as a second-line treatment for CSS 
patients, particularly in the case of neuropathy or cardiomyopathy, which are resistant to 
conventional therapy. There is not much evidence supporting the effectiveness of IVIG in 
CSS, however,  the mechanisms underlying the action of IVIG remain unclear. (Baldini et al., 
2010). In 2004 Danieli et al. published the long term effectiveness of intravenous 
immunoglobulin and plasmapheresis associated with prednisone and cyclophosphamide in 
Churg-Strauss syndrome. Complete clinical and functional recovery with a long term stable 
remission and a low incidence of side effects can be achieved by intravenous 
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immunoglobulin associated with plasmapheresis in patients with Churg-Strauss syndrome. 
Churg-Strauss syndrome (CSS) is an extremely rare disease, and even less common in 
women of childbearing age. Hot et al. (2007) in their case report not only supports the 
beneficial effect of IVIG in CSS, but also illustrates its successful and safe use in a patient 
who was pregnant. They concluded alternative indication of IVIG in ANCA associated 
vasculitides during the pregnancy. 
3.5 Behçet´s syndrome 
Behçet's syndrome is a systemic vasculitis with an unknown etiology affecting the small and 
large vessels of the venous and arterial systems. Recent European League Against 
Rheumatism guidelines are useful for the management of the disease in organ systems 
distinct from the vascular, neurological, and gastrointestinal systems. This is because of a 
lack of controlled studies evaluating such vascular, neurological, and gastrointestinal 
complications (Yazici et al., 2010).  Seider et al. (2001) reported their results in the group of 
four patients in which the use of an immunoglobulin had brought the acute inflammation, 
uncontrolled by corticosteroids and/or cyclosporine A, under control and preserved the 
remission for a period of at least 1 year. Beales (1998) reported a case report of Behçet's 
colitis. Such gastrointestinal involvement in Behçet's syndrome is relatively rare, but could 
bring significant complications (Yurdakuk et al. 1996). Treatment may be difficult and 
published report suggests intravenous immunoglobulin to be beneficial. Behçet’s colitis 
rapidly responded to IVIG, initially when the patient had failed steroid and 
immunosuppressive therapy and subsequently when IVIG was used as primary therapy. 
Leong et al. (2008) according to various reviewing american organisations calculated score 
for treatment of Behçet´s syndrome to zero (not recommended), but above mentioned 
reports advise IVIG treatment in specific situations.  
3.6 Henoch-Schönlein purpura 
Most studies concerning IVIG treatment in Henoch-Schönlein purpura are case reports and 
bring repugnant conclusions. Orbach et al. (2004) reported that IgA nephropathy and HSP 
with poor prognosis may improve with IVIG, but 5/15 patients suffered from progressive 
renal failure after treatment. Hamidou et al. (1996) reported the efficacy of intravenous 
immunoglobulin in severe gastrointestinal manifestations. Fagbemi et al. (2007) described 
one patient with massive gastrointestinal haemorrhage in isolated intestinal Henoch-
Schönlein purpura with prompt response to intravenous immunoglobulin infusion. They 
concluded that in severe cases where there is significant gastritis, IVIG provides an effective 
alternative to corticosteroids that may be employed as first-line therapy. In an open 
prospective cohort study Rostoker et al. (1994) treated 2 patients with HSP (from the group 
of 11 patients with IgA nephropathy) and concluded for all eleven patients that IVIG should 
protect renal function. On the contrary, other authors reported 3 more cases of HSP who did 
not show improvement in renal function, but rather deterioration (Orbach et al., 2004). 
3.7 Mixed cryoglobulinaemia   
Mixed cryoglobulinemia type II causes small vessel vasculitis. Vasculitis in skin, peripheral 
nerve, kidneys, gastrointestinal tract and joints is evoked by presence of circulating 
cryoglobulins of both polyclonal IgG and a monoclonal IgM rheumatoid factor that are 
directed against the IgG. The use of IVIG in mixed cryoglobulinaemia type II has been 
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reported without favorable effect and could lead to the induction of cryoglobulinaemia 
(cryoglobulinemic vasculitis) (Odum et al., 2001). In the presence of peripheral neuropathy 
vasculitis IVIG treatment showed beneficial effect (Almog et al., 2010). Until present, there is 
lack of supporting information, but according to Levy  et al. (2005) IVIG may be beneficial in 
cases of resistant vasculitic peripheral neuropathy usually connected with 
cryoglobulinaemia. IVIG should probably be considered as a sole or adjuvant treatment in 
patients for whom conventional treatment is contraindicated, or for patients in whom 
conventional treatment is failed.      
4. Economic, supervising and supply implications  
IVIG is an expensive blood product that has been used in clinical praxis. IVIG preparations 
are derived from donor blood with potential risk of such infections as hepatitis and HIV. 
The process used to prepare final products for use in humans is monitored by the 
manufacturer and the supervising institutions of particular countries for the presence of 
dangerous infectious agents. The monitoring starts with the screening of potential donors. 
Under processing, a multi-step approach that extracts the desired immunoglobulins and 
attempts to remove all other substances is used. At the end, samples of each batch are tested 
for the presence of infectious particles. While all attempts are taken to reduce the risk of 
infection, some small risk still exists.  
In last recent years, there was a marked limitation in their supply from manufacturers. This 
can be caused by several reasons, but main reason is supposed to be the increased use of 
immunoglobulin for the treatment of assorted new clinical indications, often used without 
evidence of benefit in the literature. Other liable factory which have affected supply and 
production costs have been are lack of donors and possible contamination of these human 
plasma products by infectious agents. It may carry a risk of transmitting infectious agents, 
e.g. viruses (hepatitis C) (Bjoro et al., 1994) and theoretically, the Creutzfeldt-Jakob disease 
caused by prions (Will et al., 1996).  
For example, UK Department of Health published from November 2007 to May 2008 the 
programme related to manufacturing, distribution and use of intravenous immunoglobulins 
in the country. The Demand Management Programme is a three-part initiative that consists 
of: 1) National Clinical Guidelines for the appropriate use of IVIG, 2) Demand Management 
Plan and 3) National Immunoglobulin Database. Published material also includes 
requirement for the major UK supplier of immunoglobulin to buy plasma from the USA. 
This fact significantly increased production costs. Plasma was previously sourced within the 
UK as a by-product of voluntary blood donations. Second requirement was to close a UK 
manufacturer, Scottish National Blood Transfusion Service, also resulting in reduced local 
supply. Some additional problems increasing the price of IVIG is shortage availability of 
therapeutic immunoglobulin due to reduced imports by commercial companies who market 
intravenous immunoglobulins and acute shortages caused by unexpected withdrawals of 
batches of immunoglobulin for safety reasons e.g. the introduction of further measures to 
reduce the risk of disease transmission by immunoglobulin infusions (Department of Health 
UK, 2008). The UK demand management plan restricts IVIG use where benefit is unproved 
(Vaitla & McDermott, 2010).  
In many European countries use of IVIG is mostly limited for treatment primary immune 
deficiencies where such treatment has been known to be life saving. Even though use of 
intravenous immunoglobulins in inflammatory diseases has been increased and a recent 
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literature search revealed more than 150 off-label usages of IVIG, which included 6781 
patients in clinical trials and 362 patients in case reports (Leong et al., 2008).  
Due to shortage at the same time also in the USA, prices for IVIG have been on an upward 
trend, most notably in the secondary market. Many medical professionals have reported 
that the majority of their IVIG use was applied for off-label indications. Off-label use seems 
to be increased, contributing to rising demand.  
 
Name Producer Indications Last update EMA 
Flebogamma Grifols RT, BMT, KD, ITP,GBS 09/2010 
Kiovig Baxter RT, BMT, KD, ITP,GBS 05/2008 
Privigen CSL Behring RT, BMT, KD, ITP,GBS 03/2008 
*Orfagen Orfagen PM 10/2003 
Table 1. a. IVIG indications exceeded RT in EU  (EMA) 
 
Name Producer Indication Last update FDA 
Gammagard S/D Baxter RT, KD, ITP 10/2008 
Gammagard Liquid Baxter RT 04/2005 
Iveegam E/N Baxter RT, KD N/A 
Polygam S/D Baxter RT, ITP N/A 
Carimune CSL Behring RT, ITP 10/2008 
Privigen CSL Behring RT, ITP 07/2007 
Panglobulin NF CSL Behring RT, ITP N/A 
Gamamr-P  I.V. CSL Behring RT N/A 
Flebogamma DIF Grifols RT 07/2010 
Venoglobulin-S Gfrfols RT, ITP, KD N/A 
Gammaplex Bio Products RT 10/2009 
Octagam Octapharma RT 02/2006 
Gamunex - C Talecris RT, ITP, CIDP 09/2008 
Table 1. b. IVIG indications exceeded RT by FDA in USA. (N/A – without actual FDA 
approval) 
Unexpected development in last years led all responsible representatives (EMA, FDA, 
medical professional societies, manufacturers) to coop with arose situation and postulate 
exact indications in Europe and USA respectively (Table 1a and 1b). There are less IVIG 
products with limited indications in summary of product characteristics at present market 
in comparison with the eighties. Uncertain role of IVIG in unlabeled indications is well 
established in UK Department of Health Clinical Guidelines for Immunoglobulin Use. The 
goal of submitted material is to ensure best practice across all indications, based on available 
evidence and expert opinion. Table 2 shows approved, potentially approved (grey) 
indications of IVIG in vasculitis treatment in UK (Department of Health UK, 2008).   
5. Dosage implications  
Generally accepted dosing regimes can be divided into two main groups. The first labeled 
group represents substitution (replacement) therapy used in primary and secondary 
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immunodeficiencies and the second group represents immunomodulatory therapy in 
idiopathic thrombocytopenic purpura, Kawasaki disease, Gullain-Barré syndrome, chronic 
inflammatory demyelinating polyneuropathy and polymyositis. All these indications are 
approved by EMA and FDA in Europe and USA respectively (Table 2 and 3). In replacement 
therapy (low-dose) group recommended dosis ranges from 0,2 to 0,8 g per kg of body 
weight and in immunomodulatory (high-dose) group ranges from 1,0 to 2,0 g/kg.  
The labeled use of IVIG is at present widely overlapped by unlabeled indications. These 
indications include the treatment of many immunological and idiopathic diseases involving 
nearly all organ systems. Man could say “gunshot into the unknown”. Leong et al. (2008) 
analyzed over 150 unlabeled uses of IVIG, including the most studied indications (e.g. 
multiple sclerosis, antiphospholipid syndrome in miscarriage, …) and concluded that 
evidence for unlabeled use of IVIG has been interpreted in different ways by various 




– short term 
Recommended  




KD Yes No A, Ia None 
DM, JDM Selected Seleted B, IIa CS, IS, PE 
CNS vasculitis N/A N/A IIb CS, IS 
PM N/A N/A III CS, IS, PE 
SV, AAV N/A N/A III IS 
SLE, JSLE N/A N/A III CS, IS 
Table 2. UK Department of Health guidelines for using IVIG in vasculitis (adapted).  







KD (labeled) NI 2 NI 2 2 2 2,0 
Unlabeled        
Behçet´s syndrome 0 NI NI 0 NI NI 0,0 
CCS NI NI NI 2 NI NI 2,0 
PAN NI NI NI 0 NI NI 0,0 
Systemic vasculitides 1 1 NI 0 NI NI 0,7 
Secondary vasculitides NI NI NI 0 NI NI 0,0 
WG NI NI NI 0 NI NI 0,0 
Table 3. Indication score of various US guidelines for using IVIG in vasculitis  (adapted 
according to Leong et al., 2008).  
Until present immunological mechanisms of immunomodulatory effect of IVIG are not 
clearly known. In such context a question of adequate dosage appears in the relation of 
cost/benefits of unlabeled treatment. We published (Lukán et al., 2008) an adequate 
response in a case of Wegener´s granulomatosis after lower “high-dose” regimen (1 g/kg) 
which lasts until present without any therapy, only with mild increase of cANCA and no 
clinical recurrency. Many authors published effectiveness of such lower dose regime also in 
other rheumatological and hematological indications. Genevay et al. (2001) published 
effective use of IVIG in lower doses (0,8 g/kg) but only for maintenance treatment in 
polymyositis and concluded considerable reduction in treatment costs without a negative 
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influence on patient´s health conditions. Sherer et at. (2008) reported a retrospective analysis 
the medical records of 62 patients who received low-dose of IVIG and concluded that low-
dose IVIG is a possible therapeutic option which is associated with lower cost, however 
treatment did not improved vasculitis in analyzed patients. Authors recommend IVIG only 
as an add-on therapy. Mori et al. (1988) concluded that in the treatment of acute idiopathic 
thrombocytopenic purpura there was no difference in therapeutic efficacy between the high 
and the low-dose IVIG regimen. Boman et al. (1995) achieved dramatic responses to IVIG in 
two cases of cerebral vasculitis even after the administration of the first dose (1 g/kg). One 
of the patients improved within 24 h of the administration, treatment continued at 4-week 
intervals and the patient was stable for 13 month, in spite of halving the dose of IVIG. 
Gedalia et al. (1995) reported in cutaneous polyarteritis nodosa combined with streptococcal 
infection in a dose 1 g/kg and Asano et al. (2006) in female patient with polyarteritis nodosa 
without any infection in a dose of 0,5 g/kg rapid and dramatic improvement after the first 
administration of IVIG. Monova et al. (2002) collected data on 116 patients with lupus 
nephritis who were treated with intravenous immunoglobulins. IVIG was applied in a dose 
of 0,255 g/kg. Depending on the clinical improvement afterwards the courses were repeated 
after 1 month (and every 3 months for maintenance of remission) to 7 years. Full remission 
was achieved in 36 patients. Partial remission was present in 48 patients. 32 patients went 
into end-stage renal failure and/or died. In 13/34 patients with impaired renal function 
serum creatinine levels returned to normal after treatment. Recher et al. (2010) reported a 
case report on unexpectedly successful a low-dose regimen (0,6 g/kg) in female patient with 
inclusion body myositis which costs approximately fourfold less than high-dose IVIG. In 
Henoch-Schönlein purpura some authors  (Heldrich et al., 1993, Rostoker et al., 1995, 
Ruellan et al., 1997) administered low-dose or lower limit of high-dose regimens, others 
(Rostoker et al., 1994, Lamireau et al., 2001, Fagbemi et al., 2007) strictly apply 2 g/kg. Apart 
from the dose applied all authors emphasize dramatic improvement of IVIG treatment 
already after 24 hours after beginning (Girisgen et al., 2011).  
It could be supposed that patients who respond to high-dose IVIG therapy would probably 
also respond to much lower doses, in many rheumatological indications vasculitides not 
excluded. In addition to economic reasons, low-dose regimen would likely help to reduce 
treatment related side effects. The lack of validated and generally accepted outcome 
measures as well as prospective clinical studies, makes it difficult to compare the effect of 
different interventions in different cases (Yu & Lennon, 1999).   
6. Conclusion  
Biological complexity of vasculitides and their contemporary nomenclature complicates not 
only the estimation of appropriate diagnosis but also hampers effective treatment.. 
Intravenous immunoglobulins represent one of the very often discussed alternative 
treatment modality of vasculitides. For patients who fail to achieve remission, have 
persistent low activity of inflammation and relapse, intravenous immunoglobulins could be 
used as an alternative/adjuvant immunomodulatory therapy. Mechanism of action of 
intravenous immunoglobulins is complex and its effects are not clearly understood.  
Even though many questions remain unanswered, intravenous immunoglobulins could be 
considered as an effective treatment regimen in many “off label” indications particularly in 
the cases when standard immunosuppressive regimes fail or could be harmful. In spite of 
www.intechopen.com
 
Intravenous Immunoglobulin Therapy in Primary Vasculitides 
 
161 
evidence of efficacy, dosage and timing IVIG therapy, questions of costs/benefits still 
remain insufficiently documented and controlled trials with consecutive formation of 
common guidelines are required. 
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